NGO Plans Blanket Opposition To MNC Clinical Trial Proposals In India
This article was originally published in PharmAsia News
NEW DELHI - An Indian non-profit health group has announced it plans to oppose Indian government plans to allow global companies to carry out early-stage drug trials in the country
You may also be interested in...
India’s Drug Watchdog DCGI Speeds Up Regulatory Overhaul; Single Window Clearance to Precede Central Drug Authority
MUMBAI - India's drug regulatory body, the Drug Controller General of India, is set for a comprehensive overhaul of its regulatory and administrative functions
Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances
MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).